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Abstract
Background: Pandemic and seasonal respiratory viruses are a major global health concern. Given the genetic diversity of
respiratory viruses and the emergence of drug resistant strains, the targeted disruption of human host-virus interactions is a
potential therapeutic strategy for treating multi-viral infections. The availability of large-scale genomic datasets focused on
host-pathogen interactions can be used to discover novel drug targets as well as potential opportunities for drug
repositioning.
Methods/Results: In this study, we performed a large-scale analysis of microarray datasets involving host response to
infections by influenza A virus, respiratory syncytial virus, rhinovirus, SARS-coronavirus, metapneumonia virus,
coxsackievirus and cytomegalovirus. Common genes and pathways were found through a rigorous, iterative analysis
pipeline where relevant host mRNA expression datasets were identified, analyzed for quality and gene differential
expression, then mapped to pathways for enrichment analysis. Possible repurposed drugs targets were found through
database and literature searches. A total of 67 common biological pathways were identified among the seven different
respiratory viruses analyzed, representing fifteen laboratories, nine different cell types, and seven different array platforms. A
large overlap in the general immune response was observed among the top twenty of these 67 pathways, adding validation
to our analysis strategy. Of the top five pathways, we found 53 differentially expressed genes affected by at least five of the
seven viruses. We suggest five new therapeutic indications for existing small molecules or biological agents targeting
proteins encoded by the genes F3, IL1B, TNF, CASP1 and MMP9. Pathway enrichment analysis also identified a potential
novel host response, the Parkin-Ubiquitin Proteasomal System (Parkin-UPS) pathway, which is known to be involved in the
progression of neurodegenerative Parkinson’s disease.
Conclusions: Our study suggests that multiple and diverse respiratory viruses invoke several common host response
pathways. Further analysis of these pathways suggests potential opportunities for therapeutic intervention.
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Introduction
Respiratory viruses account for seasonal colds, bronchiolitis,
acute otitis, sinusitis, croup, community-acquired pneumonia, and
exacerbation of both chronic obstructive pulmonary disease and
asthma [1]. The prevalence of pandemic Orthomyxoviridae Influenza
A Virus (FLU) from April 2009 to 2010 was estimated to be
approximately 60 million cases, 270,000 hospitalizations, and
12,000 deaths [2]. Paramyxoviridae Respiratory Syncytial Virus
(RSV) infection results in nearly two million children requiring
medical care with about 57,000 children younger than five years
hospitalized annually [3]. In one survey, RSV was the most
prevalent pathogen in children under five years with an acute
respiratory infection, followed by Adenoviridae adenovirus
(ADENO), and Picornaviridae human rhinovirus (HRV) [4].
While initially effective, pathogen gene targeted treatments
exert evolutionary selection on the infectious species often leading
to the emergence of drug resistant strains. As a result, there are
increasing clinical reports of resistance against many drugs that
directly act on viral proteins or their DNA [5,6]. In particular,
resistance to different classes of antiviral drugs is becoming more
clinically prevalent in respiratory virus infections as seen with RSV
and FLU treated with the antiviral drugs palivizumab [7], and
oseltamivir [8], respectively.
Pathogens elucidate two broad types of biochemical responses in
the host. First is the activation of the host immune system. While
the immune response is critical in combating pathogen infections,
its over-activation often exacerbates tissue damage initiated by
viral invasion [9,10]. The second response is the up-regulation of
host genes, such as protein biosynthetic pathways, that are crucial
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Interestingly, genetically distinct respiratory viruses often modulate
common host proteins and biological pathways during infection
[1]. For example, many respiratory viruses trigger similar general
airway inflammatory responses such as the expression of cytokines
interleukin-6 (HUGO gene name IL6), interleukin-8 (IL8) and
interleukin-11 (IL11), and granulocyte macrophage-colony stimu-
lating factor (CSF2). These inflammatory responses in turn initiate
IgA production, B cell differentiation and T cell stimulation [12–
16]. As a consequence, diagnosis for specific viral infections is
difficult since diverse respiratory viruses cause similar, often
indistinguishable patient symptoms [1]. However, because distinct
respiratory viruses converge on similar immune responses,
opportunities also exist for targeting host proteins and pathways
which will potentially affect multiple viral pathogens [17].
Moreover, human targets might be less susceptible to the evolution
of drug resistance due to constraints on the virus to find alternative
host pathways for its proliferation.
Individuals may experience a co-infection or sequential
infections of multiple viruses or bacteria which can complicate
both disease diagnosis and drug prescription decisions. Further-
more, patients infected by multiple pathogens may have further
complications due to drug-drug interactions, cumulative drug
toxicities and immune system suppression, as observed during
HIV and Mycobacterium tuberculosis co-infections [18,19]. Indeed, a
study in children under five years showed pervasive clinical
occurrences of co-infections involving combinations of RSV,
HRV, Paramyxoviridae Parainfluenza Virus, FLU, Coronaviridae
SARS-Coronavirus (CORON), Paramyxoviridae Metapneumonia
virus (MPNEU), Parvoviridae Human Bocavirus and ADENO [4].
Therefore, in addition to minimizing drug resistance, there is a
need for new therapeutic approaches to safely and effectively treat
co-infections by multiple viral and/or bacterial pathogens,
particularly where strain-specific diagnostics or treatments are
unavailable.
The development of new antiviral therapeutics requires a
greater understanding of the global host response when challenged
by different types of viruses. Such knowledge may lead to the
identification of novel human genome targets that are shared
across multiple viral infections as well as opportunities for re-
positioning existing drugs for the treatment of infectious diseases
[20]. Several recent studies have generated multiple mRNA
microarray gene expression datasets derived from experiments
involving the infection of human cell-lines or animal models with
one or more of the major respiratory viruses [21–23]. Through a
systematic analysis of these respiratory virus-human host gene
expression datasets, we determined common sets of genes and
pathways involved in host responses to viral infections. Among the
most significant pathways, we identified several potential new
opportunities for repurposing existing drugs for the treatment of
respiratory viral infections.
Results
Selection of mRNA Microarray Datasets
We performed a large-scale analysis of published mRNA
microarray datasets from studies involving a wide range of
respiratory viruses in human host infection models. We focused
on human mRNA array datasets in order to avoid complications
inherent in cross-species comparisons. In order to ensure
consistency in experimental conditions and reduce biases due to
noisy or poor quality datasets, we instituted an iterative process of
database querying, data filtering, and common pathway analysis
across all published human mRNA datasets for twelve relevant
respiratory viruses. These viruses initially included the double
stranded DNA viruses Herpesviridae Human cytomegalovirus
(CMV) and ADENO; the positive sense single stranded RNA
viruses CORON, Picornaviridae Coxsackievirus (COX), HRV,
Picornaviridae Echovirus (ECHO), and Picornaviridae Enterovirus
(ENTERO); and the negative sense single stranded RNA viruses
FLU, MPENU, RSV, Bunyaviridae Hantavirus (HANT) and Sin
nombre virus (SNV). This list was later narrowed to include only
the subset listed in Table 1 based on filtering processes outlined in
the Materials and Methods and shown in Figure 1.
A total of seven different respiratory viruses were analyzed,
represented by fifteen unique Gene Expression Omnibus (GEO)
datasets (indicated by GEO Series or GSE accession numbers),
nine different human cell types, and seven different array
platforms for a total of 28 unique comparisons. Note that one
dataset (GSE17156) contained two different viruses (FLU and
RSV) that were analyzed.
Candidate Dataset Filtering and Quality Control
After querying the GEO database and prescreening for obvious
non-candidate datasets such as those not associated with human
array platforms, there were at least 23 datasets associated with at
least one of the twelve respiratory viruses. However, after
considering all conditions for GEO dataset candidacy, at least
four of these datasets were excluded. In one case, an ADENO
dataset (GSE1291 [PMID unpublished]) had less than three
samples per treatment group, as did a COX (GSE712 [PMID
unpublished]) and a CMV (GSE19345 [24]) dataset. As another
example, a CMV dataset (GSE675 [25]) lacked a healthy/control
treatment group. Additionally, at least four datasets had some
comparison groups that did not fit the filters for inclusion. For
instance, an HRV (GSE13396) dataset’s original study design was
to observe differences in HRV infectivity between asthmatic and
non-asthmatic patients. The asthmatic comparison group data
were eliminated from the analysis because of potential difficulties
in distinguishing between host inflammatory responses due to viral
infections from those associated with chronic asthma. Similarly, a
combined FLU, HRV and RSV dataset (GSE17156) contained
two main patient groups. One group was classified as developing
symptoms after exposure to a single virus under study, while the
other group did not develop any symptoms after exposure. Only
the group that developed symptoms for each of the three viruses
was considered for further analysis and the asymptomatic group
was omitted. In total, 19 GEO datasets, representing 42 unique
comparisons (different time points and/or virus strains) were
analyzed for quality because they met the four requirements for
dataset candidacy.
No single dataset exhibited overall poor Quality Control (QC),
and therefore, all 19 datasets representing 42 comparison groups
were analyzed for differential expression. However, QC analysis
across all candidate datasets revealed two outliers in GSE17156
(samples GSM429252 and GSM429279), two in GSE11348
(samples GSM286647 and GSM286733), and one outlier each
in dataset GSE24132 [26] (sample GSM594166), GSE1739
(sample GSM30367), and GSE19580 (sample GSM487986) for
a total of seven samples removed from five different datasets.
An illustration of the kernel density and Principle Component
Analysis (PCA) plots generated during the QC analysis is shown in
Figure 2 for GSE17156’s RSV treatment (median of 141 hours
post infection) and RSV control (baseline) groups. Additional QC
analysis results including Median of Absolute Deviation (MAD)
score plots and pair-wise correlation maps are shown in Figure S1.
Initially, all samples except GSM429279 showed acceptable kernel
density (Figure 2a), PCA (Figure 2c), MAD score (Figure S1a) and
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was removed because: a) it did not conform to the kernel density of
the other samples; b) it fell outside of the Hotelling T2 alpha
threshold of 0.05 (represented by the superimposed elliptical on
the PCA plot), and; c) it was an outlier in both the MAD score and
pair-wise correlation plots. A second QC round was performed,
which resulted in a further non-conforming sample, GSM429252,
being discarded. Subsequent QC analysis generated acceptable
results in kernel density (Figure 2b), PCA (Figure 2d), MAD score
(Figure S1b), and pair-wise correlation (Figure S1d), thus this
dataset passed our criteria for inclusion in the analysis.
Differential Expression Analysis
All datasets exhibiting acceptable quality were analyzed for
probe differential expression. An example volcano plot is shown in
Figure S2 for RSV treatment group at peak symptoms versus
control group (data originating from GSE17156). Cutoff levels of
1.5-fold increase or decrease in probe expression levels, respec-
tively, and p-values ,0.05 were used throughout (represented by
red lines in Figure S2). All comparison groups had at least some
differentially expressed probes, although the number varied
greatly indicating potential falsely discovered probes (for example,
a comparison group within GSE18816 had 111 differentially
expressed probes while a comparison group within GSE11408 had
2533 differentially expressed probes). However, the conservative
pathway enrichment approach we employed tends to attenuate
falsely discovered genes.
There were three comparison groups that did not meet the
Least Square Mean (LSM) threshold requirement and were
excluded from the differentially expressed probe list: two of the
Figure 1. Outline of iterative filtering process. Analysis pipeline to select and quality control GEO datasets linked to respiratory virus mRNA
expression. Specific inclusion criteria are described in the Materials and Methods.
doi:10.1371/journal.pone.0033174.g001
Table 1. Profiles of GEO datasets passing all criteria filters.
Virus Type GSE Accession Reference Array Platform
1 Cell type
2 Time (hours)
2 Sample Size
3
CMV 24238 [104] HG U95 v 2.0 Monocytes 24 3/3
14816 [105] HG U133 A moDC 48 3/3
11408 [106] HG U95 v 2.0 Monocytes 4 6/6
14490 N/A Agilent G4112F moDC 6 8/6
48 6/6
CORON 1739 [107] HG Focus PBMC N.S.
*** 10/4
17400 [108] HG U133 Plus 2 BEC (2B4) 12 3/3
24 3/3
48 3/3
COX 697 N/A HG U95 v 2.0 HeLa 0.5 6/3
3 5/3
9 6/3
FLU 19580 [109] Illumina Human Ref 8, version 3 BEC 24
4 3/3
24
5 3/3
6
4 3/3
6
5 3/3
17156 [110] HG U133 A 2.0 Whole blood 80 8/8
18816 [111] HG 1.0 ST Diff. macrophage 6 3/3
HRV 11348 [112] HG U133 Plus 2 Nasal 48 31/31
13396 [113] HG U133 Plus 2 BEC 16 6/6
MPNEU 8961 [114] HG U133 Plus 2 ABEC(A549) 6 3/3
12 3/3
24 3/3
48 3/3
72 3/3
RSV 17156 [110] HG U133 A 2.0 Whole blood 141 9/9
6802 [115] HG U133 A 2.0 BEC (BEAS-2B) 4 3/3
3397 [116] HG U133 Plus 2 BEC (BEAS-2B) 4 4/4
1Microarray manufacturer is Affymetrix unless otherwise noted.
2N.S.=Not specified; moDC=Monocyte-derived dendritic cells;PBMC=Peripheral blood mononuclear cells; BEC=bronchial epithelial cells; ABEC=Alveolar BEC.
3Before individual sample removal during quality control filtering. Sample Size refers to the number of GSM samples per treatment group versus control group.
4Influenza A H3N2.
5Influenza A H11N9.
doi:10.1371/journal.pone.0033174.t001
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[unpublished] dataset, and the third comparison group was an
RSV treatment from GSE3397. After LSM filtering, 18 datasets,
or a total of 39 comparison groups remained.
Pathway Enrichment Analysis
For each comparison group, the differentially expressed probes
were mapped to their corresponding genes, and then a p-value was
assigned for each pathway map using the software GeneGo
(accessed June 2011). Next, the comparison group’s significant
pathway lists were combined to find the union of all significant
pathways (that is, the combined pathway list where all treatment
groups have at least one significant pathway). A total of 459 out of
the approximately 650 pathway maps available in MetaBase were
determined to be significant. Comparison groups having ,5%
significant pathways of the total significant pathways (that is,
comparison groups containing less than 23 significant pathways)
lead to the exclusion of eleven comparison groups from the union
list. Excluded groups were: HRV at 8 hours (eliminating one
comparison group from GSE11348), HRV at 72 hours (eliminat-
ing one comparison group from GSE17156), both strains of FLU
at 1 hour and 3 hours each and another strain at 6 hours
(eliminating three comparison groups from GSE18816), RSV at
24 hours (eliminating all comparison groups from GSE24132),
CMV at 24 and 72 hours (eliminating all comparison groups from
GSE24434 [27]), and FLU at 8 hours (eliminating all comparison
groups from GSE24533 [28]). At the end of the final step in our
filtering process, a total of 15 datasets, or 28 comparison groups
remained (Tables 1, S1 and S2).
Common Pathways to Respiratory Viral Infection
There were 67 enriched pathways in which all seven respiratory
viruses were represented by at least one comparison group (Table
S3). The list is ranked first by the viral frequency, followed by the
sum of the normalized viral expression (NVE) for each pathway.
Also shown are the differentially expressed as well as the total
number of network objects across all 28 comparisons. The top 20
enriched pathways are listed in Table 2 along with the percentage
and names of the differentially expressed genes with a viral
frequency of at least five in each pathway. Of these, the top
five pathways were chosen for further analysis and mapping.
These pathways are epidermal growth factor receptor (EGFR)
signaling, CD40 signaling, interferon-gamma (IFNG) signaling,
histamine receptor H1 (HRH1) signaling, and interleukin-17
(IL17) signaling (Figures S5. S6, S7, S8, S9; Table S4).
Additionally, the Parkin-Ubiquitin Proteasomal System (Parkin-
UPS) pathway was chosen for further analysis because it has not
been previously associated with the innate immunity and might be
an interesting new mechanism of host response to respiratory viral
infection (Figure 3).
The NVEs for differentially expressed genes with frequencies of
at least six viruses are shown in Table 3 along with their associated
pathways. The list is ranked by the greatest viral frequency, and
then by number of pathways in which the gene is differentially
expressed. The NVE values for all genes, along with associated
pathways, ranked by the greatest viral frequency, followed by the
number of pathways in which the gene is differentially expressed
are in Table S5. We ensured that the NVE was not bias toward
any particular comparison group, and indeed no single dataset
contributed to the overall NVE for any single virus (Table S2).
Hierarchical clustering on the quantile normalized fold change
values for all genes having expression values in at least 26 out of 28
comparisons (at least 90% comparisons) and significant in at least
seven comparisons (Figure S3) as well as for genes with NVE of at
least six viruses (Figure S4) did not reveal any dominant clustering
by GSE or virus type. The most consistently up-regulated genes
Figure 2. Example of quality analysis for subset of GSE17156: RSV treatment and control groups. Kernel density plot a) before and b)
after removal of samples GSM429279 and GSM429252: blue lines indicate baseline samples, green lines indicate RSV peak symptom samples
(,141 hours); PCA plot c) before and d) after removal of samples GSM429279 and GSM429252 :blue circles indicate control (baseline) samples, green
circles indicate RSV peak symptom samples (,141 hours). Ellipse represents Hotelling T2 alpha threshold of 0.05. Eigenvalues for panel c components
1 and 2 are, respectively, 119335.7 and 50356.11. Eigenvalues for panel d components 1 and 2 are, respectively, 86014.46 and 50705.63.
doi:10.1371/journal.pone.0033174.g002
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than one virus) are: nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor alpha (NFKBIA), tumor necrosis
factor alpha-induced protein 3 (TNFAIP3), chemokine C-C motif
ligand 2 (CCL2), interferon regulatory factor 1 (IRF1), prosta-
glandin-endoperoxide synthase 2 (PTGS2), chemokine C-C motif
ligand 20 (CCL20), dual specificity phosphatase 1 (DUSP1),
eukaryotic translation initiation factor 2-alpha kinase 2 (EI-
F2AK2), TNF receptor superfamily member 6 (FAS), suppressor
of cytokine signaling 1 (SOCS1), TNF receptor-associated factor 1
(TRAF1), and ubiquitin-conjugating enzyme E2L 6 (UBE2L6).
There were no consistently down-regulated mRNAs (down-
regulated in at least six viruses and up-regulated in no more than
one virus).
We sought drug repurposing candidate targets from the top five
enriched pathways and the Parkin-UPS pathway by searching the
DrugBank database, version 3.0 (http://www.drugbank.ca/
accessed August 2011) [29–31], for drugs targeting any of the 67
differentially expressed genes with a viral frequency of at least five
(Table S6). Of these, thirteen genes, or almost 20% of the original
67 genes, were associated with at least one approved small
molecule or protein therapy. There genes were: prostaglandin-
endoperoxide synthase 2 (PTGS2), TNF, matrix metallopeptidase
9 (MMP9), jun proto-oncogene (JUN), interleukin 1 beta (IL1B),
CCL2, CD86, coagulation factor III (F3), phosphoinositide-3-
kinase regulatory subunit 1 (PIK3R1), intercellular adhesion
molecule 1 (ICAM1), nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (NFKB2), Caspase 1 (CASP1), and
tubulin beta 3 (TUBB3). A selection of these genes, along with
other characteristics to evaluate their potential as drug targets such
as involvement in immune response [29–31], Jackson Laboratory
knock-in/knock-out mouse (JAX) phenotype [32], approved or
marketed small molecule drug or protein therapy, and current
indications for that drug, are listed in Table 4. Note that the
current indication may not be for the gene target listed. Mimosine
(gene target: CCL2) and Glucosamine (gene targets: NFKB2 and
MMP9) did not have a current indication, while the interactions of
Natalizumab (gene target: ICAM1) and Gallium nitrate (gene
target: ILB1) with their gene targets were unclear. Additionally,
therapies associated with PTGS2 are cyclooxygenase (COX-2)
inhibitors which have known side-effect issues thus were not
explored further. Therefore, NFKB2, ICAM1 and PTGS2 were
excluded from Table 4, leaving ten genes for potential drug
repurposing. The potential cases for drug repurposing are
discussed more in-depth for four targets; F3, IL1B, TNF and
CASP1.
Figure 3. Parkin-Ubiquitin Proteasomal System pathway with viral frequency. Viral frequencies superimposed for each of most frequently
differentially expressed proteins, where red circles are differential expression of genes by 7 viruses, orange circles are differential expression of genes
by at least 6 viruses, and blue circles are differential expression of genes by 5 viruses. See MetaCore website at http://www.genego.com/pdf/MC_
legend.pdf for figure legend and Table S4 for pathway map gene products’ corresponding HUGO gene names.
doi:10.1371/journal.pone.0033174.g003
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Analysis of mRNA Microarray Datasets
Our study used a systematic process to minimize potential
technical noise that could have arisen from our comparative
analysis of fifteen unique datasets from nine different cell types,
and seven different array platforms. These measures included
candidate dataset filtering followed by QC, differential gene
expression and pathway enrichment analyses. A total of 14 out of
42, about one third of the total comparisons, were removed as a
result of this filtering process, which is indicative of our
conservative analysis approach. We had previously used large-
scale and merged-SAM analyses in integrating large-scale micro-
array datasets involving cancer tissues from multiple laboratories
[33,34]. However, the small sample size datasets used in the
present study required a more rigorous methodology to identify
data outliers.
To our knowledge the QC analysis performed with each GEO
dataset is unique to this study. Although no dataset was completely
disregarded after QC analysis, some samples were clear outliers,
thus potentially skewing the data. Kauffmann and Huber have
demonstrated improvements in signal-to-noise ratios after per-
forming post normalization QC analysis to remove array outliers
within an experiment [35]. Those authors used MA-plot and box-
plots of the log-ratios to determine outliers instead of MAD scores,
PCA and pair-wise correlations employed in this study. Funda-
mentally, the concept of data improvement after outlier removal
applies regardless of the QC analysis approach.
Table 2. Top twenty pathways with highly expressed gene percentages and names.
Pathway % genes with VF
1 $5 Names of genes with VF $5
EGFR signaling 26 JUN, MYC, NFKBIA, STAT1, FOS, JAK2, HBEGF, DUSP1, DUSP4, PTK2, GSK3B,
MMP9, NFKB2, PIK3R1, PRKCA, SOS2, TGFA
CD40 signaling 31 IL8, JUN, NFKBIA, TNFAIP3, CCL2, FAS, IL6, IRF1, JAK2, PTGS2, TRAF1,
CCND2, CD86, ICAM1, LYN, MAP2K3, MAP3K14, MAPK14, NFKB2, PIK3R1,
TP53, TRAF5
IFNG signaling 24 MYC, STAT1, CDKN1A, EIF2AK2, IRF1, JAK2, SOCS1, STAT2, CAMK2G, CEBPB,
ICAM1, MAPK14, PIK3R1, PRKCA, PTPN11
HRH1 signaling 25 IL8, JUN, NFKBIA, FOS, IL6, TNF, CSF2, F3, GNAQ, GNB4, GNG12, ICAM1,
MAPK14, MMP9, PLA2G4C, PLCB1, PPP3CA, PRKCA
IL17 signaling 31 CEBPD, IL8, JUN, NFKBIA, CCL2, CCL20, CXCL1, FOS, IL6, JAK2, PTGS2,
CEBPB, CSF2, GSK3B, ICAM1, IL1B, MAP2K3, MAP3K14, MAPK14, MMP9,
NFKB2, PIK3R1
CSF2 signaling 25 EGR1, MYC, NFKBIA, CCL2, FOS, JAK2, MCL1, CSF2, LYN, NFKB2, PIK3R1,
PIM1, PTPN11, SOS2
IL1 signaling 36 IL8, JUN, NFKBIA, STAT1, FOS, IL6, IRF1, PTGS2, TNF, EDN1, F3, FOSB, FOSL1,
FOSL2, IL1B, IL1RAP, JUNB, MAP2K3, MAPK14, SERPINE1
CCR5 signaling 19 JUN, STAT1, FOS, JAK2, CCL4, CCL5, GNAQ, GNB4, GNG12, MAP2K3,
MAPK14, PLCB1, PPP3CA, PRKCA, TIAM1
Chemokines-adhesion 16 CCR1, CXCL1, IL8, JUN, MYC, THBS1, CCL2, PLAUR, ARPC1B, CD47, FLNA,
GNB4, GNG12, GSK3B, ITGA6, NFKB2, PIK3R1, PLAT, PLAU, PTK2, RAP1GAP,
SERPINE1, SOS2, WASL
Cytoskeleton via TGF, WNT 10 JUN, MYC, CDKN1A, FOXO3, PLAUR, SERPING1, ARPC1B, CDKN2B, GSK3B,
MAP2K3, MAPK14, PIK3R1, PLAT, PLAU, PTK2, SERPINE1, SOS2, TGFBR2,
WASL
IL15 signaling 19 IL15, IL8, MYC, NFKBIA, FOS, IL6, MCL1, IL15RA, MAPK14, PIK3R1, PLCB1,
PTK2, SOS2
IL22 signaling 17 JUN, MYC, STAT1, FOS, JAK2, MCL1, CD86, HLA-DOB, MAPK14, SOCS3,
STAT4
Histamine-dendritic signaling 16 IL6, IL8, CCL2, CCL5, CD86, CREM, GNAQ, GNB4, GNG12, IL1B, IRF8, PRKACB,
TNF
GnRH signaling 12 ATF3, DUSP1, EGR1, FOS, JUN, DUSP4, FOSL1, FOSL2, GNAQ, MAPK14,
PRKACB
Prolactin receptor signaling 24 JUN, MYC, STAT1, IRF1, JAK2, NMI, NR3C1, OAS1, SOCS1, CEBPB, IRS1,
PIK3R1, PTPN11, SOCS3, SOS2
JUN mediated metabolism 22 JUN, CDKN1A, FAS, FOS, PLAUR, TNFAIP6, FOSB, FOSL1, FOSL2, JUNB
Parkin-UPS 18 CASP1, CASP8, CCNE1, CUL1, HSPA1A, HSPA1B, HSPA1L, HSPA4, HSPA6,
HSPA8, PSMD10, TUBB3, UBE2L6
Cytoskeleton remodeling 9 MYC, CDKN1A, JUN, PLAUR, ITGA6, MAPK14, MYH10, PIK3R1, PLAT, PLAU,
PTK2, SERPING1, TGFBR2, WASL
IL2 signaling 15 MYC, EGR1, FOS, JUN, NFKBIA, FOSL1, FOSL2, NFKB2, PIK3R1, SOCS3
Gastrin signaling 19 CXCL1, CXCL2, FOS, HBEGF, IL8, IRS1, JUN, NFKBIA, GNAQ, MAPK14, MEF2A,
PIK3R1, PTGS2, PTK2
1VF=Viral Frequency.
doi:10.1371/journal.pone.0033174.t002
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Despite the diverse nature of the microarray data analyzed here,
we found a large overlap between comparison groups in significant
pathways, especially the immune system. Of the top twenty
enriched pathways, eighteen are associated with immune response
(Table 2). For example, EGFR signaling is known to be activated
during infection by respiratory viruses FLU [36] and ENTERO
[37,38]. CD40 signaling is associated with CORON [39], RSV
[40], and the general immune response [41]. Interferon gamma
(IFNG) signaling is initiated by FLU [42] and RSV [43], while
interleukin 1 signaling is stimulated by FLU [42]. As components
of the general immune response, interferon and interleukin
pathways are activated by infectious agents such as hepatitis C
virus (HCV), HIV and tuberculosis as well as chronic diseases like
Crohn’s disease, diabetes, and metastatic melanoma [44,45]. The
overall relationships between the transitory host immunity
response launched by pathogenic infections versus that seen in
chronic autoimmune and neurodegenerative diseases are complex
and an intense area of investigation [46]. In addition, there are
considerations about subtle shifts in gene function roles in different
cell tissue types amongst the various diseases. Thus, we are
cautious about any linkages between pathways involved in
infections and those of chronic diseases as implied by our analysis
without further validation studies.
Potential Role of Parkin-UPS Pathway in Viral Infection
Parkin (PARK2) is an E3-ubiqutin ligase associated with the
progression of the neurodegenerative disorder Parkinson’s disease.
[47]. As a central hub protein in the Parkin-UPS pathway,
PARK2 ubiquinates proteins encoded by septin 5 (SEPT5) [48],
tubulin alpha and beta [49], and the glycosylated form of
synuclein, alpha (SNCA) [50] for degradation by the 26S
proteasome. PARK2 also ubiquinates synuclein, alpha interacting
protein (SNCAIP) for regulation of SNCA [51], interacts with
STIP1 homology and U-box containing protein 1 E3 ubiquitin
protein ligase (STUB1) to enhance ubiquitination of G protein-
coupled receptor 37 (GPR37), [52] (which associates with F-box
and WD repeat domain containing 7 (FBXW7)), and cullin 1
(CUL1) to ubiquitinate cyclin E [53]. PARK2 is deactivated by
protolytic cleavage by CASP1 and Caspase 8 (CASP 8) [54] and
can be activated by either heat shock protein 70kD (HSPA4) or
STUB1 [52].
The Parkin-UPS pathway is not commonly associated with
general immune response to viral infection. However, other
Table 3. Normalized viral expression and pathway inclusion grid for genes with viral frequency $6.
Gene Name
1 CMV CORON COX FLU HRV MPENU RSV Included in pathway
Down Up Down Up Down Up Down Up Down Up Down Up Down Up EGFR HRH1 IFNG IL17 CD40Parkin
JUN 22/5 3/4 1/3 22/6 21/2 5/5 1/3 X X X X
NFKBIA 1/5 3/4 1/3 1/6 2/2 4/5 1/3 X X X X
IL8 22/5 1/5 2/4 1/3 21/6 1/6 1/2 5/5 1/3 X X X
MYC 22/5 21/4 2/3 1/6 1/2 3/5 1/3 X X
STAT1 5/5 21/4 1/4 21/3 4/6 21/2 1/2 5/5 21/3 1/3 X X
CEBPD 21/5 1/4 1/3 1/6 1/2 21/5 2/5 1/3 X
TNFAIP3 3/5 2/4 1/3 1/6 2/2 5/5 1/3 X
CASP1 4/5 21/4 1/4 21/3 2/6 21/2 1/2 4/5 1/3 X
JAK2 21/5 2/5 1/4 2/6 1/2 4/5 21/3 1/3 X X X X
FOS 23/5 3/4 2/3 21/6 21/5 3/5 1/3 X X X
IL6 21/5 4/5 1/4 21/6 2/6 2/2 5/5 1/3 X X X
CCL2 3/5 1/3 1/6 1/2 21/5 4/5 1/3 X X
IRF1 5/5 1/4 2/6 1/2 21/5 4/5 1/3 X X
PTGS2 3/5 1/4 1/3 21/6 1/6 1/2 5/5 X X
CCL20 1/5 2/4 21/6 2/6 2/2 3/5 1/3 X
CDKN1A 2/5 1/3 21/6 2/6 1/2 21/5 1/3 X
CXCL1 21/5 1/5 2/4 1/3 22/6 2/2 3/5 X
DUSP1 1/5 3/4 2/3 22/6 1/6 3/5 1/3 X
DUSP4 1/5 21/4 1/3 1/6 21/5 3/5 1/3 X
EIF2AK2 3/5 1/3 4/6 1/2 4/5 1/3 X
FAS 5/5 1/3 1/6 21/2 1/2 5/5 1/3 X
HBEGF 3/5 2/3 24/6 2/2 5/5 1/3 X
SOCS1 3/5 1/4 3/6 2/2 4/5 1/3 X
STAT2 4/5 21/4 1/4 21/6 2/6 1/2 4/5 1/3 X
TNF 21/5 4/5 1/4 1/3 2/6 2/2 21/5 2/5 X
TRAF1 3/5 21/4 1/4 1/3 1/6 1/2 3/5 X
UBE2L6 5/5 1/4 4/6 1/2 5/5 1/3 X
1The first 8 genes are differentially expressed in seven viruses, and the remaining 19 genes are differentially expressed in six viruses.
doi:10.1371/journal.pone.0033174.t003
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host defense [55,56]. Associations between influenza infection and
neuroinflammation in early onset autosomal recessive Parkinson’s
disease have been recently suggested [57–59]. At least one factor
in the progression of Parkinson’s disease is the formation of
neuotoxic Lewy bodies due to increases in SNCA. Increases in
SNCA are believed to be the result of loss-of-function mutations in
PARK2 which cause disruptions in the protein’s localization and
solubility [60–62]. Polymorphisms in the gene PARK2 have also
been associated with susceptibility to infectious diseases such as
leprosy, typhoid fever and paratyphoid fever, although the exact
mechanism is still unclear [63,64]. Jang et al. observed activation of
SNCA in mouse nervous tissue long after pathogenic H5N1 FLU
infection where the increased levels of SNCA mirror those found
in Parkinson’s disease [57]. Similarly, recent findings from Rohn
and Catlin indicate FLU as a potential causative factor for
Parkinson’s disease [58]. Indeed, links between FLU and other
neurodegenerative diseases have been suggested, and these include
seizures, transverse myelitis, expressive aphasia, syncope, enceph-
alitis, neuromyelitis optica, and central nervous system disease in
general [65–67].
PARK2 itself has a low signal at the mRNA level which might
be due to its significant regulation by post-translation processes
[52,54]. Further studies are needed to determine the mechanism
Table 4. Putative targets with associated drugs.
Gene
1 Involvement in immunity [29–31] JAX phenotype
3 Drug Name Current Indication
3 [29–31,103]
CCL2 activator
2 not available Danazol endometriosis, benign breast disorders,
angioedema
F3 activator none Coagulation factor VIIa hemorrhagic complications in
hemophilia A and B
PIK3R1 activator; used by viruses abnormal humoral immune
response & B cell physiology
Isoproterenol mild/transient heart block; asthma and
chronic bronchitis
CD86 activator
2 abnormal humoral immune
response; dec. T cell
proliferation
Abatacept RA; polyarticular JIA
Antithymocyte globulin renal transplant rejection
IL1B activator inc. susceptibility to bacterial
infection
Minocycline bacterial infections
Canakinumab CAPS
TNF activator
2 abnormal immune system
physiology, inc. susceptibility to
viral infection, inc./dec.
susceptibility to bacterial
infection
Infliximab Crohn’s disease; ulcerative colitis; RA,
JIA & psoriatic arthritis; ankylosing
spondylitis
Pranlukast reduces bronchospasm caused by
allergic reaction
Amrinone congestive heart failure
Etanercept, Adalimumab RA; JIA (Etanercept); psoriatic arthritis
(Adalimumab); ankylosing spondylitis;
severe plaque psoriasis (Etanercept);
Crohn’s disease (Adalimumab)
Thalidomide multiple myeloma and erythema
nodosum leprosum
Chloroquine malaria; RA
Amrinone congestive heart failure
Clenbuterol bronchodilator for asthma attacks
MMP9 used by viruses abnormal histamine physiologyMarimastat cancer
Minocycline bacterial infections
Captopril renovascular hypertension; congestive
heart failure; left ventricular
dysfunction; nephropathy
JUN activator
2 none Irbesartan hypertension; nephropathy in type 2
diabetic patients
Arsenic trioxide acute promyelocytic leukemia
CASP1 activator
2 dec. inflammatory response,
inc./dec. susceptibility to
bacterial infection
Minocycline bacterial infections
TUBB3 used by viruses not available Ixabepilone breast cancer
1CASP1 and TUBB3 are members of Parkin-UPS pathway.
2Strongly associated with innate immune response activation.
3RA=rheumatoid arthritis; JIA=juvenile idiopathic arthritis; CAPS=cryopyrin-associated periodic syndromes; inc.=increased; dec.=decreased.
doi:10.1371/journal.pone.0033174.t004
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Drug Repurposing Against Respiratory Viruses
Our analysis suggests several potential repurposing opportuni-
ties for launched drugs against host-viral targets (Table 4). This
assumption is based on the occurrence of genes that are
differentially expressed in infection models for at least five of the
seven respiratory viruses, have involvement in a number of
relevant pathways related to host immune response, and encode
for known drug targets. The drugs associated with this gene list do
not have current indications as anti-viral therapies, although
Pranlukast and Clenbuterol are prescribed for relief of lung
disorders such as bronchospasm after allergic reactions and
asthma bronchoconstriction during asthma attacks, respectively.
Also, Minocycline, sometimes called Minocin, is a broad-spectrum
tetracycline antibiotic as well as a caspase 1 (CASP1) inhibitor
while Chloroquine is a well-known anti- malaria drug [29–31]. In
fact, eight of the ten drug repurposing gene targets are involved in
activation of the innate immune response, while the remaining two
have some evidence of virus modulation. Potential drug repurpos-
ing opportunities for F3, IL1B, TNF, and MMP9, as well as the
Parkin-UPS pathway gene product CASP1, are discussed below.
Coagulation Factor III (F3). F3 normally binds to the native
cofactor VII or VIIa to induce the blood coagulation cascade.
Treatment with recombinant coagulation factor VIIa promotes
blood coagulation in hemophiliacs [29–31]. Esmon et al. [68]
suggest that coagulation could be used therapeutically to modulate
inflammation responses and vice versa, but also caution about the
danger of increased incidence of thrombosis. The consistent up-
regulation of F3 across five viruses suggests that the immune-
coagulation axis is already initiated and supplemental F3
activation may cause thrombosis complications. Further study is
needed to develop therapeutics that could balance between innate
immune response triggered by coagulation factor VIIa therapy
and stabilization of the antithrombotic state.
Interleukin 1 beta (IL1B). IL1B is a cytokine involved in
inflammatory response, cell proliferation, differentiation, and
apoptosis. IL1B is specifically cleaved into its active form by the
protease CASP1 after which it activates the NLRP3
inflammasome [29–31,69]. Indeed, IL1B is consistently up
regulated across CMV, FLU, HRV, MPENU and RSV which
likely correlates with inflammasome activation. However, over-
expression of IL1B causes multiple inflammatory disorders [69].
Antagonists or neutralizers of IL1B, such as Canakinumab, could
potentially reduce inflammation damage associated with viral
infection.
Tumor Necrosis Factor (TNF). TNF has a wide range of
biological functions including modulation of immune response to
pathogen assault. Mouse TNF knock-out phenotypes include
abnormal immune system physiology, increased susceptibility to
viral infection, and both increased and decreased susceptibility to
bacterial infection [29–31]. In our study, TNF is mostly up
regulated in infections by CMV, CORON, COX, and FLU but
directionally ambiguous for MPNEU and not expressed under
RSV. While total disruption of TNF function would be deleterious
to the host, there are instances where partial TNF inhibition
provides a clinical benefit in patients with viral complications
[70,71].
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist that
reduces bronchospasm caused by an allergic reaction, usually with
asthmatic individuals. This drug inhibits TNF-alpha by blocking
macrophage cysteinyl leukotriene 1 (cysLTC4, D4) receptors [72]
or suppression of NF-kappa B activation [73]. Pranlukast has been
recently shown to be beneficial not only in cases of respiratory
syncytial virus postbronchiolitis, but also in a wide variety of other
diseases with strong inflammatory complications such as cystic
fibrosis, cancer, atherosclerosis, eosinophils cystitis, otitis media,
capsular contracture, and eosinophilic gastrointestinal disorders
[71].
Amrinone is a type 3 pyridine phosphodiesterase inhibitor used
in the treatment of congestive heart failure and is an inhibitor of
TNF [74]. Phosphodiesterase inhibitors have been shown to alter
immune response [75–78] and, in one case, specifically through
TNF [79]. Amrinone is known to modulate pro- and anti-
inflammatory factors in endotoxin-stimulated cells [80]. Type 4
phosphodiesterase inhibitors have been used to treat RSV-induced
airway hyper-responsiveness and lung eosinophilia [81]. There-
fore, indirect evidence suggests that Armirone may be beneficial in
respiratory viral infection situations by inhibiting TNF via type 4
phosphodiesterase, although this has yet to be seen in clinical
studies.
Matrix Metallopeptidase 9 (MMP9). MMP9 encodes a
matrix metallopeptidase that degrades type IV and V collagens,
and is implicated in arthritis and metastasis [29–31]. We can only
speculate on the role MMP9 plays in infection. Our analysis finds
the gene to be up-regulated for three viruses while down-regulated
for two different viruses. In other studies, MMP9 has been
observed to be up-regulated after exposure to double stranded
RNA and is important to airway injury [82], specifically by RSV
[83]. MMP9 expression is induced by IL1B [84] which, as
mentioned above, is an activator of the NLRP3 inflammasome
[85]. MMP9 inhibitors such as Marimastat, Minocycline or
Captopril, could be beneficial assuming that the protein is co-
opted by the infecting virus for tissue remodeling. Blocking MMP9
may also reduce inflammatory damage by down-regulating the
inflammasome.
Caspase 1 (CASP1). In the case of the Parkin-UPS pathway,
inhibiting tubulin-beta formation may reduce viral proliferation
given that FLU utilize acetylated tubulin for protein trafficking
[86] and increases in neuronal class III TUBB occur after COX
infection [87]. A CASP1 inhibitor such as Minocycline could be
used to increase PARK2 ubiquitinase activity, in turn decreasing
the TUBA or TUBB availability.
As mentioned above, CASP1 is a component of the NLRP3
inflammasome, activating the precursor to IL1B [69]. Therefore, a
CASP1 inhibitor would have an antagonist relationship with IL1B,
hence the inflammasome. Further, CASP1 inhibitors would be
agonists for PARK2, thereby reducing accumulation of SNCA. In
this regard, CASP1 inhibitors may not only prevent unnecessary
NLRP3 inflammasome activation via ILB1, but may also reduce
accumulation of neurotoxic Lewy bodies through activation of
PARK2.
However, caspases are not specific to the Parkin-UPS pathway
and inhibition in this regard may result in toxicity or other
complications [88]. Additionally, mouse JAX phenotypes for
CASP1 show both increased and decreased susceptibility to
bacterial infection, as well as decreased inflammatory response.
While CASP1 inhibition may prove beneficial in terms of
increasing inflammatory responses, it is ambiguous in terms of
benefit for bacterial infections. In our analysis, the expression of
CASP1 and TUBB3 is also somewhat variable across virus types.
Therefore, more study is needed specifically on the role of caspase
and tubulin in host response to respiratory virus infection.
Future Directions
Modulation of any human host pathway for the treatment of
viral infections has potential drawbacks with respect to toxicity and
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to help combat viral pathogens, the treatment is known to cause an
array of side-effects related to toxicity including confusion,
lethargy, impaired mental status, numbness, tingling, fevers, chills,
headaches, anorexia and sepsis [89,90]. Another caveat is that
some proteins are beneficial if up-regulated during initial viral
infection but have detrimental effects if over-activated for
prolonged periods. Thus determining the desired mechanism
and direction of therapeutic intervention requires careful study.
Although targeting host-pathogen interactions is a challenging
therapeutic approach, there are considerable upside benefits with
respect to overcoming pathogen-mediated drug resistance and the
capability of treating multiple, co-infecting pathogens. Our study
suggests several potential human-host proteins that could be
targets of future therapeutics as well as some possible drug
candidates for further investigations of repurposing against
respiratory virus infections.
Materials and Methods
Data Sources for Human mRNA Datasets
The National Center for Biotechnology Information’s GEO
database (http://www.ncbi.nlm.nih.gov/geo/ (accessed between
January and July 2011) was searched for human mRNA datasets
for twelve respiratory viruses. These viruses were the double
stranded DNA viruses Herpesviridae, human cytomegalovirus and
Adenoviridae Adenovirus; the positive sense single stranded RNA
viruses Coronaviridae SARS-Coronavirus, Picornaviridae Coxsackievi-
rus, Picornaviridae Human Rhinovirus, Picornaviridae Echovirus, and
Picornaviridae Enterovirus; and the negative sense single stranded
RNA viruses Orthomyxoviridae Influenza A virus, Paramyxoviridae
Metapenumonia virus, Paramyxoviridae Respiratory syncytial virus,
Bunyaviridae Hantavirus and Sin nombre virus. Subsequent filtering
steps (Figure 1) reduced the number of viruses with suitable
datasets to seven species (Table 1).
All analyzed GEO datasets contain at least one ‘‘treatment
group’’ and ‘‘control group’’. ‘‘Treatment’’ was the experimental
variable under study, usually a virus type, strain, or time point.
‘‘Group’’ was a collection of individual ‘‘samples’’, or replicates,
each of which originates from their own microarray chip.
‘‘Comparison group’’ was the treatment group compared to a
control group. A particular dataset may have more than one
comparison group. All criteria for dataset inclusion in the final
analysis were chosen prior to the analysis.
Dataset Selection and Quality Control Processes
Dataset candidacy filtering consisted of four criteria: 1) the
dataset must contain at least 3 samples per treatment or control
group because a sample size any less would mean a loss in
statistical power for subsequent analysis; 2) the microarray
platform must be supported by either Affymetrix, Agilent or
Illumina due to probe mapping abilities of the software used in
subsequent analysis; 3) each gene expression profile had to be
derived from human cells and probed using a human-based
genome microarray platform and not other species; and 4) the
dataset must contain at least one wild-type infection treatment
group (i.e., unmodified virus strain or infectivity mechanism) and
at least one healthy control group (i.e., no genetic or media
modifications such as gene knock outs or inhibitors, respectively).
Prior to quality control (QC) analysis, we pre-screened and pre-
processed each dataset. Normalized raw data and the study design
table were imported from the GEO databases (The data was
assumed to be normalized by robust multi-array average, but in
some cases the published study used an alternative normalization
method). Where appropriate, the intensity values were log2
transformation. Various experimental parameters such as time
point, virus strain and number of replicates were extracted from
the study design tables. Samples irrelevant to the main study
design were marked for segregation or exclusion from our
downstream analysis, but not excluded from quality assessment.
These were classified as ‘‘failing to meet treatment specification’’ at
the candidate filtering step. Studies that had a large number of
missing intensity values (over 10%) were annotated and flagged.
The QC analysis assessed each sample in the dataset for kernel
density, PCA, MAD, and pair-wise Pearson correlation such that:
1) the kernel density was normally distributed; 2) after PCA values
were within the Hotelling T2 alpha level threshold of 0.05 [91–
93]; 3) MAD score scores were in the range of +3t o23 with no
outliers [94]; and 4) inner-treatment group pair wise correlations
for samples derived from a single cell were $0.97 or $0.90 if
taken from individual donors [94]. Figures were created using
Array Studio software, version 4.1. (Omicsoft Corporation,
Research Triangle Park, NC, USA [95]). During subsequent
analysis, each comparison group was treated separately, regardless
of dataset origination, in order to gain a wider, less bias view of
representative genes and pathways.
mRNA Array Expression and Pathway Analysis
Once a comparison group passed the QC analysis filters, LSM
values were calculated for each probe using Array Studio in order
to reduce the number of false positives due to low probe intensity
values. Probes within each of the filtered datasets were tested for
biological and statistical relevance using the Array Studio
implementation of fold change and statistical models, respectively.
Specifically, to determine a probe’s fold change expression when
compared to control, the geometric mean of each probe’s log2
transformed intensity value within a treatment was generated, and
then normalized to the corresponding control group’s geometric
mean. The treatment versus control data were fitted to a general
linear model, and associated p-values for each probe were
calculated using a modified t-test [96]. Thus, to be considered
differentially expressed, each probe within a comparison group
must have a p-value ,0.05 after general linear model test and a
fold change in either direction of 1.5.
To visualize a comparison group’s significance and fold change,
volcano plots were generated using Array Studio of a probe’s
2log(p-value) versus its transformed fold change (FC) value
according to the following piece-wise function:
E(FC)~
{(log2( FC jj )),FCƒ{1
z(log2(FC)),FC§z1

The differentially expressed probes were mapped to their
corresponding genes using MetaCore/MetaBase (GeneGo), a
software/database package that creates biological pathways and
networks from gene lists (database accessed June 2011) [97,98]. If
more than one probe mapped to a gene, the probe with the highest
magnitude fold change value was used for that gene. Thus, the
mapped differentially expressed probe list became the differentially
expressed gene list for each comparison group.
The differentially expressed gene lists from each comparison
group were analyzed for enriched pathways using GeneGo. A p-
value for each of the 658 pathway maps in the MetaBase were
generated for each comparison group using a hypergeometric test
[99]. In order for a pathway to be considered enriched, each
comparison group must contain pathways that have a p-value
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pathway list was ranked by its viral frequency, which is defined by
the number of viruses represented by at least one comparison
group, and then by the sum of Normalized Viral Expression or
NVE for each enriched pathway. The NVE for each pathway was
calculated using the number of comparisons containing significant
pathways within a virus type relative to the number of
comparisons within that virus type. For example, if one out of
four FLU comparisons for pathway A were significant, the NVE
for FLU would be 1/4. Ranking the pathways in this fashion
resulted in a clearer determination of pathways shared across
multiple viruses, irrespective of time, strain type, or number of
comparison groups.
After examining the ranked pathway list described above, the
top five significant pathways and an additional pathway
representing a unique mechanism were further analyzed. With
each map, the proteins were labeled according to the number of
viruses in which the transcript was differentially expressed thus
yielding the viral frequency for that protein. In cases where a
protein complex was made up of subunits, the greatest magnitude
fold change value for any subunit was chosen to represent the
entire complex. GeneGo was used for the visualization of this
pathway map.
Similar to the pathway NVE, the NVE for each gene within
these six chosen pathways was calculated using the number of
comparisons containing either up or down regulated genes for
each protein within a virus type relative to the number of
comparisons within that virus type. For example, if two out of
three RSV comparisons for gene X were up-regulated, gene X’s
NVE for RSV would be 2/3.
We performed complete linkage and correlation distance
hierarchical clustering using ArrayStudio on quantile normalized
fold change values to determine the separation qualities of the
analyzed data [100]. Clustering was performed on genes that had
expression values for at least 90% of the total number of
comparisons. We used the Matlab function ‘knnimpute’ to impute
missing fold change values using k-Nearest Neighbors estimation
(MATLAB version 7.11 (R2010b), Mathworks, Cambridge MA,
2010) [101,102].
Drug Repurposing
Approved or marketed small molecule and protein therapeutics
for each of the differentially expressed proteins modulated by 5 or
more respiratory viruses were obtained from the DrugBank
database, version 3.0 (http://www.drugbank.ca/ accessed August
2011) [29–31]. We only considered those drugs that were
launched products with experimental and clinical evidence of
direct interaction with gene product in question. The therapy’s
interaction with the target and approved indication were identified
using a combination of DrugBank, the drug manufacturer’s
information page, and the National Center for Biotechnology
Information’s PubChem (http://pubchem.ncbi.nlm.nih.gov/ ac-
cessed September 2011) [103] and Gene (http://www.ncbi.nlm.
nih.gov/gene/ accessed September 2011) databases. Supplemen-
tal evidence of mechanism of action was obtained from immune or
infection-related Jackson Laboratory knock-in/knock-out mouse
(JAX) phenotype (http://www.jax.org/ accessed September 2011)
[32].
Supporting Information
Figure S1 Sample of quality analysis for subset of
GSE17156: RSV treatment and control groups using
MAD score and correlations. MAD score plot as a function of
time point a) before and b) after removal of samples GSM429279
and GSM429252; Baseline group correlation heat map c) before
and d) after removal of samples GSM429279 and GSM429252
(not shown): white blocks indicate pair-wise Pearson correlation
below 0.97, dark blue indicate perfect (1.00) pair-wise Pearson
correlation.
(TIF)
Figure S2 Volcano plot of a probe differential expres-
sion analysis for the RSV symptomatic treatment from
GSE17156. Each point on the figure represents an individual
mRNA array chip probe. Horizontal axis is estimate and vertical
axis is 2log(p-value). Red lines dictate threshold cutoffs of p-value
0.05 (2log (p-value)<1.3) and fold change +/21.5 (estimate<+/
20.58).
(TIF)
Figure S3 Hierarchical clustering of the fold change
values on genes differentially expressed in at least 7
comparisons. The horizontal axis contains each of the 28
different comparisons labeled by virus, GSE and time point. The
vertical axis shows clustering of 1,274 genes that are differentially
expressed in at least 7 of the 28 comparisons and have an
expression value in at least 26 comparisons. Yellow indicates a fold
change value of 3.0 or greater; blue indicates a fold change value
of 23.0 or less; white indicates a fold change value of 0.0.
(TIF)
Figure S4 Hierarchical clustering of the fold change
values on genes from top pathways with an NVE of at
least 6 viruses (Table 3). The horizontal axis contains each of
the 28 different comparisons labeled by virus, GSE and time point.
The vertical axis shows the clustering of 27 genes from the top five
and Parkin-UPS pathways that have an NVE of at least 6 and
have an expression value in at least 26 comparisons. For genes
present in more than one of the five pathways, the number of
participating pathways is indicated by the count of ‘‘*’’ before the
gene name. Color scheme is as described for Figure S3.
(TIF)
Figure S5 Epidermal Growth Factor Receptor signaling
pathway with viral frequency. Viral frequencies superim-
posed for each of most frequently differentially expressed proteins,
where red circles are differential expression of genes by 7 viruses,
orange circles are differential expression of genes by at least 6
viruses, and blue circles are differential expression of genes by 5
viruses. See MetaCore website at http://www.genego.com/pdf/
MC_legend.pdf for figure legend and Table S4 for pathway map
gene products’ corresponding HUGO gene names.
(TIF)
Figure S6 CD40 signaling pathway with viral frequency.
Viral frequencies superimposed for each of most frequently
differentially expressed proteins, where red circles are differential
expression of genes by 7 viruses, orange circles are differential
expression of genes by at least 6 viruses, and blue circles are
differential expression of genes by 5 viruses. See MetaCore website
at http://www.genego.com/pdf/MC_legend.pdf for figure legend
and Table S4 for pathway map gene products’ corresponding
HUGO gene names.
(TIF)
Figure S7 Interferon-gamma signaling pathway with
viral frequency. Viral frequencies superimposed for each of
most frequently differentially expressed proteins, where red circles
are differential expression of genes by 7 viruses, orange circles are
differential expression of genes by at least 6 viruses, and blue
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MetaCore website at http://www.genego.com/pdf/MC_legend.
pdf for figure legend and Table S4 for pathway map gene
products’ corresponding HUGO gene names.
(TIF)
Figure S8 Histamine Receptor H1 signaling pathway
with viral frequency. Viral frequencies superimposed for each
of most frequently differentially expressed proteins, where red
circles are differential expression of genes by 7 viruses, orange
circles are differential expression of genes by at least 6 viruses, and
blue circles are differential expression of genes by 5 viruses. See
MetaCore website at http://www.genego.com/pdf/MC_legend.
pdf for figure legend and Table S4 for pathway map gene
products’ corresponding HUGO gene names.
(TIF)
Figure S9 Interleukin-17 signaling pathway with viral
frequency. Viral frequencies superimposed for each of most
frequently differentially expressed proteins, where red circles are
differential expression of genes by 7 viruses, orange circles are
differential expression of genes by at least 6 viruses, and blue
circles are differential expression of genes by 5 viruses. See
MetaCore website at http://www.genego.com/pdf/MC_legend.
pdf for figure legend and Table S4 for pathway map gene
products’ corresponding HUGO gene names.
(TIF)
Table S1 GSM (GEO Sample) annotation for all studies
considered.
(XLSX)
Table S2 Gene list of fold change, p-value and passes
LSM threshold for the 28 analyzed comparisons.
(XLSX)
Table S3 Results of pathway enrichment analysis.
(XLSX)
Table S4 Gene symbol-network object name mapping.
(XLSX)
Table S5 Normalized viral expression and pathway
inclusion grid.
(XLSX)
Table S6 Number of experimental and marketed drugs
associated with the top genes from analyzed pathways.
(XLSX)
Acknowledgments
We thank Vinod Kumar for his assistance in computational analysis.
Author Contributions
Conceived and designed the experiments: SS MM-S JB. Performed the
experiments: SS. Analyzed the data: SS WD AT. Wrote the paper: SS
MM-S WD AT JB.
References
1. Nichols GW, Peck Campbell AJ, Boeckh M (2008) Respiratory Viruses Other
than Influenza Virus: Impact and Therapeutic Advances. Clin Biol Rev 21:
274–290.
2. Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, et al. (2011)
Estimating the burden of 2009 pandemic influenza A (H1N1) in the United
States (April 2009–April 2010). Clin Infect Dis 52 Suppl 1: S75–S82. ciq012
[pii];10.1093/cid/ciq012 [doi].
3. Meissner HC, Bocchini JA, Brady MT, Hall CB, Kimberlin DW, et al. (2009)
The role of immunoprophylaxis in the reduction of disease attributable to
respiratory syncytial virus. Pediatrics 124: 1676–1679. 124/6/1676
[pii];10.1542/peds.2009-2346 [doi].
4. Bezerra PG, Britto MC, Correia JB, Duarte MC, Fonceca AM, et al. (2011)
Viral and atypical bacterial detection in acute respiratory infection in children
under five years. PLoS One 6: e18928. 10.1371/journal.pone.0018928 [doi].
5. Cassino L, Benetti S, Fay F, Tanno H, Quarleri J (2011) Unsuccessful therapy
with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B
infection with previous resistance to lamivudine: a fourteen-year evolution of
hepatitis B virus mutations. BMC Infect Dis 11: 178. 1471-2334-11-178
[pii];10.1186/1471-2334-11-178 [doi].
6. Bonavia A, Franti M, Pusateri KE, Kuhen K, Seepersaud M, et al. (2011)
Identification of broad-spectrum antiviral compounds and assessment of the
druggability of their target for efficacy against respiratory syncytial virus (RSV).
Proc Natl Acad Sci U S A 108: 6739–6744. 1017142108 [pii];10.1073/
pnas.1017142108 [doi].
7. Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, et al. (2011)
Analysis of respiratory syncytial virus preclinical and clinical variants resistant
to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
J Infect Dis 203: 674–682. jiq100 [pii];10.1093/infdis/jiq100 [doi].
8. [Anonymous] (2011) Weekly epidemiological record:Recommended composi-
tion of influenza virus vaccines for use in the 2011–2012 northern hemisphere
influenza season. . pp 81–92.
9. Oslund KL, Baumgarth N (2011) Influenza-induced innate immunity:
regulators of viral replication, respiratory tract pathology & adaptive immunity.
Future Virol 6: 951–962.
10. Torchinsky MB, Garaude J, Blander JM (2010) Infection and apoptosis as a
combined inflammatory trigger. Curr Opin Immunol 22: 55–62. S0952-
7915(10)00004-X [pii];10.1016/j.coi.2010.01.003 [doi].
11. Nagy PD, Pogany J (2011) The dependence of viral RNA replication on co-
opted host factors. Nat Rev Microbiol. nrmicro2692 p. [pii];10.1038/
nrmicro2692 [doi].
12. Sayama K, Kajiya K, Sugawara K, Sato S, Hirakawa S, et al. (2010)
Inflammatory mediator TAK1 regulates hair follicle morphogenesis and
anagen induction shown by using keratinocyte-specific TAK1-deficient mice.
PLoS One 5: e11275. 10.1371/journal.pone.0011275 [doi].
13. Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA (1997) Interleukin
(IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med
185: 461–469.
14. Subauste MC, Jacoby DB, Richards SM, Proud D (1995) Infection of a human
respiratory epithelial cell line with rhinovirus. Induction of cytokine release and
modulation of susceptibility to infection by cytokine exposure. J Clin Invest 96:
549–557. 10.1172/JCI118067 [doi].
15. Einarsson O, Geba GP, Zhu Z, Landry M, Elias JA (1996) Interleukin-11:
stimulation in vivo and in vitro by respiratory viruses and induction of airways
hyperresponsiveness. J Clin Invest 97: 915–924. 10.1172/JCI118514 [doi].
16. Churchill L, Friedman B, Schleimer RP, Proud D (1992) Production of
granulocyte-macrophage colony-stimulating factor by cultured human tracheal
epithelial cells. Immunology 75: 189–195.
17. Tan SL, Ganji G, Paeper B, Proll S, Katze MG (2007) Systems biology and the
host response to viral infection. Nat Biotechnol 25: 1383–1389. nbt1207-1383
[pii];10.1038/nbt1207-1383 [doi].
18. Diedrich CR, Flynn JL (2011) HIV-1/mycobacterium tuberculosis coinfection
immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun 79:
1407–1417. IAI.01126-10 [pii];10.1128/IAI.01126-10 [doi].
19. Piggott DA, Karakousis PC (2011) Timing of antiretroviral therapy for HIV in
the setting of TB treatment. Clin Dev Immunol 2011: 103917. 10.1155/2011/
103917 [doi].
20. Padhy BM, Gupta YK (2011) Drug repositioning: Re-investigating existing
drugs for new therapeutic indications. J Postgrad Med 57: 153–160.
jpgm_2011_57_2_153_81870 [pii];10.4103/0022-3859.81870 [doi].
21. Brown JR, Magid-Slav M, Sanseau P, Rajpal DK (2011) Computational
biology approaches for selecting host-pathogen drug targets. Drug Discov
Today 16: 229–236. S1359-6446(11)00026-2 [pii];10.1016/j.drudis.2011.01.
008 [doi].
22. McGarvey PB, Huang H, Mazumder R, Zhang J, Chen Y, et al. (2009)
Systems integration of biodefense omics data for analysis of pathogen-host
interactions and identification of potential targets. PLoS One 4: e7162.
10.1371/journal.pone.0007162 [doi].
23. Schwegmann A, Brombacher F (2008) Host-directed drug targeting of factors
hijacked by pathogens. Sci Signal 1: re8. scisignal.129re8 [pii];10.1126/
scisignal.129re8 [doi].
24. Luo MH, Hannemann H, Kulkarni AS, Schwartz PH, O’Dowd JM, et al.
(2010) Human cytomegalovirus infection causes premature and abnormal
differentiation of human neural progenitor cells. J Virol 84: 3528–3541.
JVI.02161-09 [pii];10.1128/JVI.02161-09 [doi].
25. Browne EP, Wing B, Coleman D, Shenk T (2001) Altered cellular mRNA
levels in human cytomegalovirus-infected fibroblasts: viral block to the
accumulation of antiviral mRNAs. J Virol 75: 12319–12330. 10.1128/
JVI.75.24.12319-12330.2001 [doi].
Common Mechanisms of Respiratory Viral Infection
PLoS ONE | www.plosone.org 13 March 2012 | Volume 7 | Issue 3 | e3317426. Thornburg NJ, Shepherd B, Crowe JE, Jr. (2010) Transforming growth factor
beta is a major regulator of human neonatal immune responses following
respiratory syncytial virus infection. J Virol 84: 12895–12902. JVI.01273-10
[pii];10.1128/JVI.01273-10 [doi].
27. Knoblach T, Grandel B, Seiler J, Nevels M, Paulus C (2011) Human
Cytomegalovirus IE1 Protein Elicits a Type II Interferon-Like Host Cell
Response That Depends on Activated STAT1 but Not Interferon-gamma.
PLoS Pathog 7: e1002016. 10.1371/journal.ppat.1002016 [doi].
28. Lee SM, Chan RW, Gardy JL, Lo CK, Sihoe AD, et al. (2010) Systems-level
comparison of host responses induced by pandemic and seasonal influenza A
H1N1 viruses in primary human type I-like alveolar epithelial cells in vitro.
Respir Res 11: 147. 1465-9921-11-147 [pii];10.1186/1465-9921-11-147 [doi].
29. Overington J (2009) ChEMBL. An interview with John Overington, team
leader, chemogenomics at the European Bioinformatics Institute Outstation of
the European Molecular Biology Laboratory (EMBL-EBI). Interview by
Wendy A. Warr. J Comput Aided Mol Des 23: 195–198. 10.1007/s10822-009-
9260-9 [doi].
30. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008)
DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic
Acids Res 36: D901–D906. gkm958 [pii];10.1093/nar/gkm958 [doi].
31. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, et al. (2006)
DrugBank: a comprehensive resource for in silico drug discovery and
exploration. Nucleic Acids Res 34: D668–D672. 34/suppl_1/D668
[pii];10.1093/nar/gkj067 [doi].
32. The Jackson Laboratory (2011) Mouse Mutant Resource Web Site.
33. Dawany NB, Tozeren A (2010) Asymmetric microarray data produces gene
lists highly predictive of research literature on multiple cancer types. BMC
Bioinformatics 11: 483. 1471-2105-11-483 [pii];10.1186/1471-2105-11-483
[doi].
34. Dawany NB, Dampier WN, Tozeren A (2011) Large-scale integration of
microarray data reveals genes and pathways common to multiple cancer types.
Int J Cancer 128: 2881–2891. 10.1002/ijc.25854 [doi].
35. Kauffmann A, Huber W (2010) Microarray data quality control improves the
detection of differentially expressed genes. Genomics 95: 138–142. S0888-
7543(10)00004-2 [pii];10.1016/j.ygeno.2010.01.003 [doi].
36. Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C (2010) The
epidermal growth factor receptor (EGFR) promotes uptake of influenza A
viruses (IAV) into host cells. PLoS Pathog 6: 10.1371/journal.ppat.1001099
[doi].
37. Tung WH, Hsieh HL, Lee IT, Yang CM (2011) Enterovirus 71 modulates a
COX-2/PGE2/cAMP-dependent viral replication in human neuroblastoma
cells: role of the c-Src/EGFR/p42/p44 MAPK/CREB signaling pathway.
J Cell Biochem 112: 559–570. 10.1002/jcb.22946 [doi].
38. Tung WH, Hsieh HL, Lee IT, Yang CM (2011) Enterovirus 71 induces
integrin beta1/EGFR-Rac1-dependent oxidative stress in SK-N-SH cells: role
of HO-1/CO in viral replication(1). J Cell Physiol10.1002/jcp.22677 [doi].
39. Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT (2009) Severe acute
respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines
exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-
derived macrophages and dendritic cells. J Virol 83: 3039–3048. JVI.01792-08
[pii];10.1128/JVI.01792-08 [doi].
40. Soukup JM, Becker S (2003) Role of monocytes and eosinophils in human
respiratory syncytial virus infection in vitro. Clin Immunol 107: 178–185.
S152166160300038X [pii].
41. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, et al. (1994) The
CD40 antigen and its ligand. Annu Rev Immunol 12: 881–922. 10.1146/
annurev.iy.12.040194.004313 [doi].
42. Barbe F, Atanasova K, Van RK (2011) Cytokines and acute phase proteins
associated with acute swine influenza infection in pigs. Vet J 187: 48–53.
S1090-0233(09)00488-2 [pii];10.1016/j.tvjl.2009.12.012 [doi].
43. Senft AP, Taylor RH, Lei W, Campbell SA, Tipper JL, et al. (2010)
Respiratory syncytial virus impairs macrophage IFN-alpha/beta- and IFN-
gamma-stimulated transcription by distinct mechanisms. Am J Respir Cell Mol
Biol 42: 404–414. 2008-0229OC [pii];10.1165/rcmb.2008-0229OC [doi].
44. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, et al. (2007)
Down-regulation of the interferon signaling pathway in T lymphocytes from
patients with metastatic melanoma. PLoS Med 4: e176. 06-PLME-RA-0927R2
[pii];10.1371/journal.pmed.0040176 [doi].
45. Maedler K, Dharmadhikari G, Schumann DM, Storling J (2009) Interleukin-1
beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 9:
1177–1188. 10.1517/14712590903136688 [doi].
46. Gonzalez-Navajas JM, Lee J, David M, Raz E (2012) Immunomodulatory
functions of type I interferons. Nat Rev Immunolnri3133 [pii];10.1038/
nri3133 [doi].
47. Chaugule VK, Burchell L, Barber KR, Sidhu A, Leslie SJ, et al. (2011)
Autoregulation of Parkin activity through its ubiquitin-like domain. EMBO J
30: 2853–2867. emboj2011204 [pii];10.1038/emboj.2011.204 [doi].
48. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, et al. (2000) Parkin
functions as an E2-dependent ubiquitin-protein ligase and promotes the
degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceeding of
the National Academy of Sciences of the United States of America 97:
13354–13359.
49. Ren Y, Zhao J, Feng J (2003) Parkin binds to alpha/beta tubulin and increases
their ubiquitination and degradation. The Journal of Neuroscience 23:
3316–3324.
50. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, et
al. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from
human brain: implications for Parkinson’s disease. Science 293: 263–269.
10.1126/science.1060627 [doi];1060627 [pii].
51. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, et al. (2001) Parkin
ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications
for Lewy-body formation in Parkinson disease. Nat Med 7: 1144–1150.
10.1038/nm1001-1144 [doi];nm1001-1144 [pii].
52. Takahashi R, Imai Y (2003) Pael receptor, endoplasmic reticulum stress, and
Parkinson’s disease. J Neurol 250 Suppl 3: III25–III29. 10.1007/s00415-003-
1305-8 [doi].
53. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, et al.
(2003) Parkin is a component of an SCF-like ubiquitin ligase complex and
protects postmitotic neurons from kainate excitotoxicity. Neuron 37: 735–749.
S0896627303000849 [pii].
54. Kahns S, Kalai M, Jakobsen LD, Clark BF, Vandenabeele P, et al. (2003)
Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J Biol Chem
278: 23376–23380. 10.1074/jbc.M300495200 [doi];M300495200 [pii].
55. Jiang X, Chen ZJ (2011) The role of ubiquitylation in immune defence and
pathogen evasion. Nat Rev Immunol 12: 35–48. nri3111 [pii];10.1038/
nri3111 [doi].
56. Zhang D, Zhang DE (2011) Interferon-stimulated gene 15 and the protein
ISGylation system. J Interferon Cytokine Res 31: 119–130. 10.1089/
jir.2010.0110 [doi].
57. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, et al. (2009) Highly
pathogenic H5N1 influenza virus can enter the central nervous system and
induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A
106: 14063–14068. 0900096106 [pii];10.1073/pnas.0900096106 [doi].
58. Rohn TT, Catlin LW (2011) Immunolocalization of influenza a virus and
markers of inflammation in the human Parkinson’s disease brain. PLoS One 6:
e20495. 10.1371/journal.pone.0020495 [doi];PONE-D-11-03510 [pii].
59. Jang H, Boltz DA, Webster RG, Smeyne RJ (2009) Viral parkinsonism.
Biochim Biophys Acta 1792: 714–721. S0925-4439(08)00156-7 [pii];10.1016/
j.bbadis.2008.08.001 [doi].
60. Cookson MR, Lockhart PJ, McLendon C, O’Farrell C, Schlossmacher M, et
al. (2003) RING finger 1 mutations in Parkin produce altered localization of
the protein. Hum Mol Genet 12: 2957–2965. 10.1093/hmg/ddg328
[doi];ddg328 [pii].
61. Gu WJ, Corti O, Araujo F, Hampe C, Jacquier S, et al. (2003) The C289G and
C418R missense mutations cause rapid sequestration of human Parkin into
insoluble aggregates. Neurobiol Dis 14: 357–364. S0969996103001529 [pii].
62. Wang C, Tan JM, Ho MW, Zaiden N, Wong SH, et al. (2005) Alterations in
the solubility and intracellular localization of parkin by several familial
Parkinson’s disease-linked point mutations. J Neurochem 93: 422–431.
JNC3023 [pii];10.1111/j.1471-4159.2005.03023.x [doi].
63. Ali S, Vollaard AM, Widjaja S, Surjadi C, van d V, et al. (2006) PARK2/
PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever.
Clin Exp Immunol 144: 425–431. CEI3087 [pii];10.1111/j.1365-
2249.2006.03087.x [doi].
64. Mira MT, Alcais A, Nguyen VT, Moraes MO, Di FC, et al. (2004)
Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427:
636–640. 10.1038/nature02326 [doi];nature02326 [pii].
65. Landau YE, Grisaru-Soen G, Reif S, Fattal-Valevski A (2011) Pediatric
Neurologic Complications Associated With Influenza A H1N1. Pediatr Neurol
44: 47–51. S0887-8994(10)00385-1 [pii];10.1016/j.pediatrneurol.2010.08.011
[doi].
66. Toovey S (2008) Influenza-associated central nervous system dysfunction: a
literature review. Travel Med Infect Dis 6: 114–124. S1477-8939(08)00048-3
[pii];10.1016/j.tmaid.2008.03.003 [doi].
67. Nakamura Y, Ikeda K, Yoshii Y, Ito H, Hirayama T, et al. (2011) Influenza-
associated Monophasic Neuromyelitis Optica. Intern Med 50: 1605–1609.
JST.JSTAGE/internalmedicine/50.5027 [pii].
68. Esmon CT, Xu J, Lupu F (2011) Innate immunity and coagulation. J Thromb
Haemost 9 Suppl 1: 182–188. 10.1111/j.1538-7836.2011.04323.x [doi].
69. Menu P, Vince JE (2011) The NLRP3 inflammasome in health and disease:
the good, the bad and the ugly. Clin Exp Immunol10.1111/j.1365-
2249.2011.04440.x [doi].
70. Luna T, Santos SB, Nascimento M, Porto MA, Muniz AL, et al. (2011) Effect
of TNF-alpha production inhibitors on the production of pro-inflammatory
cytokines by peripheral blood mononuclear cells from HTLV-1-infected
individuals. Braz J Med Biol Res 44: 1134–1140. S0100-879X2011007500140
[pii].
7 1 . R i c c i o n iG ,B u c c i a r e l l iT ,M a n c i n iB ,D iI C ,D ’ O r a z i oN( 2 0 0 7 )
Antileukotriene drugs: clinical application, effectiveness and safety. Curr
Med Chem 14: 1966–1977.
72. Ichiyama T, Kajimoto M, Hasegawa M, Hashimoto K, Matsubara T, et al.
(2007) Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced
matrix metalloproteinase-9 in human monocytes/macrophages. Clin Exp
Allergy 37: 608–614. CEA2692 [pii];10.1111/j.1365-2222.2007.02692.x [doi].
73. Tomari S, Matsuse H, Machida I, Kondo Y, Kawano T, et al. (2003)
Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-
Common Mechanisms of Respiratory Viral Infection
PLoS ONE | www.plosone.org 14 March 2012 | Volume 7 | Issue 3 | e33174specific tumour necrosis factor alpha production and nuclear factor kappa B
nuclear translocation in peripheral blood monocytes from atopic asthmatics.
Clin Exp Allergy 33: 795–801. 1656 [pii].
74. Giroir BP, Beutler B (1992) Effect of amrinone on tumor necrosis factor
production in endotoxic shock. Circ Shock 36: 200–207.
75. Matsumori A (1997) The use of cytokine inhibitors. A new therapeutic insight
into heart failure. Int J Cardiol 62 Suppl 1: S3–12.
76. Crocker IC, Townley RG, Khan MM (1996) Phosphodiesterase inhibitors
suppress proliferation of peripheral blood mononuclear cells and interleukin-4
and -5 secretion by human T-helper type 2 cells. Immunopharmacology 31:
223–235.
77. Essayan DM, Huang SK, Kagey-Sobotka A, Lichtenstein LM (1997)
Differential efficacy of lymphocyte- and monocyte-selective pretreatment with
a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and
cytokine gene expression. J Allergy Clin Immunol 99: 28–37.
S0091674997000079 [pii].
78. Szczypka M, Obminska-Mrukowicz B (2010) Modulating effects of nonselec-
tive and selective phosphodiesterase inhibitors on lymphocyte subsets and
humoral immune response in mice. Pharmacol Rep 62: 1148–1158.
79. Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, et
al. (1995) Differential regulation of human monocyte-derived TNF alpha and
IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
J Pharmacol Exp Ther 272: 1313–1320.
80. Nemeth ZH, Szabo C, Hasko G, Salzman AL, Vizi ES (1997) Effect of the
phosphodiesterase III inhibitor amrinone on cytokine and nitric oxide
production in immunostimulated J774.1 macrophages. Eur J Pharmacol 339:
215–221. S0014-2999(97)01392-7 [pii].
81. Ikemura T, Schwarze J, Makela M, Kanehiro A, Joetham A, et al. (2000) Type
4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced
airway hyper-responsiveness and lung eosinophilia. J Pharmacol Exp Ther
294: 701–706.
82. Voss A, Gescher K, Hensel A, Nacken W, Kerkhoff C (2011) Double-stranded
RNA induces MMP-9 gene expression in HaCaT keratinocytes by tumor
necrosis factor-alpha. Inflamm Allergy Drug Targets 10: 171–179. IA-DT# 61
[pii].
83. Li W, Shen HH (2007) Effect of respiratory syncytial virus on the activity of
matrix metalloproteinase in mice. Chin Med J (Engl) 120: 5–11.
84. Yoo HG, Shin BA, Park JS, Lee KH, Chay KO, et al. (2002) IL-1beta induces
MMP-9 via reactive oxygen species and NF-kappaB in murine macrophage
RAW 264.7 cells. Biochem Biophys Res Commun 298: 251–256.
S0006291X02024312 [pii].
85. Menu E, Muller-Trutwin MC, Pancino G, Saez-Cirion A, Bain C, et al. (2005)
First Dominique Dormont International Conference on ‘‘Host-pathogen
interactions in chronic infections - viral and host determinants of HCV,
HCMV, and HIV infections’’. Retrovirology 2: 24. 1742-4690-2-24
[pii];10.1186/1742-4690-2-24 [doi].
86. Husain M, Harrod KS (2011) Enhanced acetylation of alpha-tubulin in
influenza A virus infected epithelial cells. FEBS Lett 585: 128–132. S0014-
5793(10)00928-2 [pii];10.1016/j.febslet.2010.11.023 [doi].
87. Tsueng G, Tabor-Godwin JM, Gopal A, Ruller CM, Deline S, et al. (2011)
Coxsackievirus preferentially replicates and induces cytopathic effects in
undifferentiated neural progenitor cells. J Virol 85: 5718–5732. JVI.02261-10
[pii];10.1128/JVI.02261-10 [doi].
88. Best SM (2008) Viral subversion of apoptotic enzymes: escape from death row.
Annu Rev Microbiol 62: 171–192. 10.1146/annurev.micro.62.081307.163009
[doi].
89. Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of
interferon biology, clinical applications, and toxicities. Oncologist 6: 34–55.
90. Hertzog P, Forster S, Samarajiwa S (2011) Systems biology of interferon
responses. J Interferon Cytokine Res 31: 5–11. 10.1089/jir.2010.0126 [doi].
91. Pearson K (1901) On lines and planes of closest fit to systems of points in space.
Phil Mag. pp 559–572.
92. Hotelling H (1933) Analysis of a complex of statistical variables into principal
components. J Educ Psychol 24: 417–520.
93. Jolliffe TI (2002) Principal Component Analysis Springer.
94. Chen K Microarray Data analysis using Arraystudio.
95. Omicsoft (2011) Array Studio, version 4.1.1.58 [computer program]. Research
Triangle Park, NC, USA.
96. Johnston G SAS Software to Fit the Generalized Linear Model.
97. Ekins S, Nikolsky Y, Bugrim A, Kirillov E, Nikolskaya T (2007) Pathway
mapping tools for analysis of high content data. Methods Mol Biol 356:
319–350. 1-59745-217-3:319 [pii].
98. Nikolsky Y, Kirillov E, Zuev R, Rakhmatulin E, Nikolskaya T (2009)
Functional analysis of OMICs data and small molecule compounds in an
integrated ‘‘knowledge-based’’ platform. Methods Mol Biol 563: 177–196.
10.1007/978-1-60761-175-2_10 [doi].
99. Draghici S, Khatri P, Martins RP, Ostermeier GC, Krawetz SA (2003) Global
functional profiling of gene expression. Genomics 81: 98–104.
S0888754302000216 [pii].
100. Antoine Lucas (10 A.D.) Another Multidimensional Analysis Package, version.
101. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, et al. (2001)
Missing value estimation methods for DNA microarrays. Bioinformatics 17:
520–525.
102. The MathWorks I (2010) MATLAB, version 7.11 [computer program].
Massachusetts, .
103. Bolton EE, Wang Y, Thiessen PA, Bryant SH (2008) PubChem: Integrated
Platform of Small Molecules and Biological Activities. Ann Reports in Comp
Chem 4.
104. Nogalski MT, Chan G, Stevenson EV, Gray S, Yurochko AD (2011) Human
cytomegalovirus-regulated paxillin in monocytes links cellular pathogenic
motility to the process of viral entry. J Virol 85: 1360–1369. JVI.02090-10
[pii];10.1128/JVI.02090-10 [doi].
105. Mezger M, Bonin M, Kessler T, Gebhardt F, Einsele H, et al. (2009) Toll-like
receptor 3 has no critical role during early immune response of human
monocyte-derived dendritic cells after infection with the human cytomegalo-
virus strain TB40E. Viral Immunol 22: 343–351. 10.1089/vim.2009.0011
[doi].
106. Chan G, Nogalski MT, Bentz GL, Smith MS, Parmater A, et al. (2010) PI3K-
dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by
epidermal growth factor receptor and inhibits apoptosis in short-lived
monocytes. J Immunol 184: 3213–3222. jimmunol.0903025 [pii];10.4049/
jimmunol.0903025 [doi].
107. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, et al. (2005)
Expression profile of immune response genes in patients with Severe Acute
Respiratory Syndrome. BMC Immunol 6: 2. 1471-2172-6-2 [pii];10.1186/
1471-2172-6-2 [doi].
108. Yoshikawa T, Hill TE, Yoshikawa N, Popov VL, Galindo CL, et al. (2010)
Dynamic innate immune responses of human bronchial epithelial cells to
severe acute respiratory syndrome-associated coronavirus infection. PLoS One
5: e8729. 10.1371/journal.pone.0008729 [doi].
109. Hsu AC, Barr I, Hansbro PM, Wark PA (2010) Human influenza is more
effective than avian influenza at antiviral suppression in airway cells.
Am J Respir Cell Mol Biol 44: 906–913.
110. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, III, et al. (2009) Gene
expression signatures diagnose influenza and other symptomatic respiratory
viral infections in humans. Cell Host Microbe 6: 207–217. S1931-
3128(09)00251-0 [pii];10.1016/j.chom.2009.07.006 [doi].
111. Lee SM, Gardy JL, Cheung CY, Cheung TK, Hui KP, et al. (2009) Systems-
level comparison of host-responses elicited by avian H5N1 and seasonal H1N1
influenza viruses in primary human macrophages. PLoS One 4: e8072.
10.1371/journal.pone.0008072 [doi].
112. Proud D, Turner RB, Winther B, Wiehler S, Tiesman JP, et al. (2008) Gene
expression profiles during in vivo human rhinovirus infection: insights into the
host response. Am J Respir Crit Care Med 178: 962–968. 200805-670OC
[pii];10.1164/rccm.200805-670OC [doi].
113. Bochkov YA, Hanson KM, Keles S, Brockman-Schneider RA, Jarjour NN, et
al. (2010) Rhinovirus-induced modulation of gene expression in bronchial
epithelial cells from subjects with asthma. Mucosal Immunol 3: 69–80.
mi2009109 [pii];10.1038/mi.2009.109 [doi].
114. Bao X, Sinha M, Liu T, Hong C, Luxon BA, et al. (2008) Identification of
human metapneumovirus-induced gene networks in airway epithelial cells by
microarray analysis. Virology 374: 114–127. S0042-6822(07)00850-1
[pii];10.1016/j.virol.2007.12.024 [doi].
115. Mayer AK, Muehmer M, Mages J, Gueinzius K, Hess C, et al. (2007)
Differential recognition of TLR-dependent microbial ligands in human
bronchial epithelial cells. J Immunol 178: 3134–3142. 178/5/3134 [pii].
116. Huang YC, Li Z, Hyseni X, Schmitt M, Devlin RB, et al. (2008) Identification
of gene biomarkers for respiratory syncytial virus infection in a bronchial
epithelial cell line. Genomic Med 2: 113–125. 10.1007/s11568-009-9080-y
[doi].
Common Mechanisms of Respiratory Viral Infection
PLoS ONE | www.plosone.org 15 March 2012 | Volume 7 | Issue 3 | e33174